BioSpace News Archive

Accelus announced enhancements to its sales team with the promotion of Lisa Jacobs to Vice President of Sales, Jim Fox to East U.S. VP of Sales, and Jay Shellhammer to West U.S. VP of Sales.

Taysha Gene Therapies, Inc. today announced that its annual stockholder meeting will be held on Friday, June 17, 2022 at 10 am ET via webcast.

Ortho Regenerative Technologies Inc., a clinical-stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, is pleased to report on the progress of its U.S. Phase I/II rotator cuff tear repair clinical trial.

XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce its participation in the BIO International Convention 2022, being held June 13th through 16th, 2022.

Altamira Therapeutics Ltd. announced positive top-line data from its exploratory Phase 2 TRAVERS trial with AM-125 in acute vertigo and provided an update on its development plans.

Hollister Incorporated, a global medical device company, has been awarded a three-year group purchasing agreement for Urological products with vizient, Inc., the nation’s largest member-driven health care performance improvement company.

Airway Management, Dallas-based manufacturer of the most independently studied custom oral appliance in the world, announces their non-custom myTAP™ is now proven equally effective to their custom TAP™.

Dompé farmaceutici S.p.A (“Dompé”) today announced results from its Phase 2 clinical trial demonstrating that, in patients in severe COVID-19 Pneumonia, Reparixin led to an improvement in clinical outcomes when compared with the standard of care, a larger phase 3 clinical study is needed to confirm these results.

On June 14-15, the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee will meet to consider granting Emergency Use Authorization (EUA) for COVID-19 vaccinations for children under age 5.

An experimental formulation of a hydrogel, injected into spinal discs, proved safe and effective in substantially relieving chronic low back pain caused by degenerative disc disease (DDD), according to new research presented at the Society of Interventional Radiology Annual Scientific Meeting, in Boston.